Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic
A version of this article was previously published on PharmaPhorum.
Trust in life science companies has fluctuated since the start of the pandemic. The reputation of COVID-19 vaccine makers understandably soared early on, as clinical trials were started and completed in record time, giving hopes to millions of people in lockdown. Since then, inconsistent messaging around the need for booster shots, as well as side effects–no matter how rare–have tarnished their name. Likewise, trust in the overall health sector is currently 2 percentage points below January 2020 levels, and far below (11 percentage points) May 2021 levels. One survey puts the percentage of persons with trust in the pharmaceutical industry in 2021 at only 50% in the UK and Canada, with the corresponding percentage in the US being even lower, at 47%. India currently has the highest percentage of trust, at 80%. Read the full blog article here: https://www.impetusdigital.com/2022/05/10/trust-and-transparency-in-pharma/
Trust in life science companies has fluctuated since the start of the pandemic. The reputation of COVID-19 vaccine makers understandably soared early on, as clinical trials were started and completed in record time, giving hopes to millions of people in lockdown. Since then, inconsistent messaging around the need for booster shots, as well as side effects–no matter how rare–have tarnished their name. Likewise, trust in the overall health sector is currently 2 percentage points below January 2020 levels, and far below (11 percentage points) May 2021 levels. One survey puts the percentage of persons with trust in the pharmaceutical industry in 2021 at only 50% in the UK and Canada, with the corresponding percentage in the US being even lower, at 47%. India currently has the highest percentage of trust, at 80%. Read the full blog article here: https://www.impetusdigital.com/2022/05/10/trust-and-transparency-in-pharma/
